Douglas Ney MD (He/Him)

Neurooncology

Professor, Neurology and Neurosurgery, University of Colorado School of Medicine Vice-Chair Education, Department of Neurology

Join to View Full Profile

12631 E. 17th AvenueAcademic Office 1, MS B185Aurora, CO 80045
Phone+1 303-724-2184
Fax+1 303-724-2213

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Neuro-Oncology, 2007 - 2009
University of Vermont Medical CenterResidency, Neurology, 2004 - 2007
University of Vermont Medical CenterInternship, Internal Medicine, 2003 - 2004
University of Rochester School of Medicine and DentistryClass of 2003

Certifications & Licensure

CO State Medical License 2009 - 2025
NY State Medical License 2007 - 2011
VT State Medical License 2003 - 2007
American Board of Psychiatry and Neurology Neurology
United Council of Neurologic SubspecialtiesCertification in Neuro-Oncology

Awards, Honors, & Recognition

Fellow AAN
5280 Top Doc 5280 Magazine, 2019
Academy of Medical Educators University of Colorado School of Medicine, 2018
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Join now to see all

Clinical Trials

A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma Start of enrollment: 2005 Nov 01
Completed
Phase 1
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme Start of enrollment: 2010 Sep 16
Completed
Phase 2
Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
ACTIVE_NOT_RECRUITING
NA
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
COMPLETED
PHASE1, PHASE2
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response Start of enrollment: 2016 Jul 12
Terminated
Phase 2
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma Start of enrollment: 2017 Dec 07
ACTIVE_NOT_RECRUITING
PHASE2
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2017 Jul 24
COMPLETED
PHASE1, PHASE2
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma Start of enrollment: 2019 Jun 17
RECRUITING
PHASE1, PHASE2
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Start of enrollment: 2016 Jul 01
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

15 citations
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.
Kevin A David, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin
American Journal of Hematology. 2023-06-01
4 citations
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort.
Prashasti Agrawal, Kevin A David, Zhengming Chen, Suchitra Sundaram, Seo-Hyun Kim
Leukemia & Lymphoma. 2023-05-01
ANA Investigates: The Future of Biomarkers in Alzheimer Disease.
Suzanne E Schindler, Douglas E Ney, Adeline L Goss, Gil Rabinovici
Annals of Neurology. 2022-08-01

Journal Articles

The Neurologic Assessment in Neuro-Oncology (NANO) Scale as an Assessment Tool for Survival in Patients with Primary Glioblastoma
Denise Damek, Kevin O Lillehei, D Ryan Ormond, Chad G Rusthoven, A Samy Youssef, Timothy H Ung, Douglas E Ney, Neurosurgery